Non-allergic angioedema from angiotensin converting enzyme inhibitors (ACE-I) is thought to be bradykinin-mediated and is therefore resistant to standard anaphylaxis therapies of epinephrine, antihistamines, and corticosteroids. This evidence concerns the gene ACE and anaphylaxis.